Related Experiment Videos
[Observation of curative effect of refined interferon-alpha on viral pneumonia in infants]
Abstract:
Fifteen cases of viral pneumonia in infants were treated with refined interferon-alpha and antibiotics. Clinical symptoms of the cases with IFN-alpha were relieved in 1.40-2.79 days, earlier than those of the control. Clinical recovery time was on the average shorter than that of the control by 1.9 days, and complete recovery by 1.5 days. The difference is statistically significant. It suggested that the clinical effect of IFN-alpha together with antibiotics is better than that of antibiotics alone. There was no significant change between the experimental and control groups in absolute lymphocyte count Ig and T-cell, but OKT3 increased and OKT8 decreased slightly. The study shows that IFN is an effective and safe administration for viral pneumonia.
Insights
Interferon-alpha (IFN-alpha) combined with antibiotics significantly speeds recovery for infants with viral pneumonia. This combination therapy offers a safe and effective treatment option, outperforming antibiotics alone.
Area of Science:
- Pediatrics
- Virology
- Immunology
Context:
- Viral pneumonia is a common respiratory infection in infants, posing significant health risks.
- Current treatments primarily rely on antibiotics, which are ineffective against viral pathogens.
- Interferon-alpha (IFN-alpha) is a cytokine with known antiviral properties.
Purpose:
- To evaluate the efficacy and safety of refined interferon-alpha (IFN-alpha) in combination with antibiotics for treating viral pneumonia in infants.
- To compare the clinical outcomes of infants treated with IFN-alpha and antibiotics versus those treated with antibiotics alone.
Summary:
- Fifteen infants with viral pneumonia received refined IFN-alpha and antibiotics. Symptom relief occurred significantly faster (1.40-2.79 days) compared to the control group.
- Overall clinical recovery was shorter by an average of 1.9 days, and complete recovery by 1.5 days in the IFN-alpha group.
- While lymphocyte counts and immunoglobulin levels remained unchanged, specific T-cell markers (OKT3, OKT8) showed slight alterations, indicating a modulated immune response.
Impact:
- IFN-alpha combined with antibiotics demonstrates superior clinical efficacy compared to antibiotics alone for infant viral pneumonia.
- The treatment regimen is deemed safe and effective, offering a valuable therapeutic option for this pediatric condition.
- This study supports the use of interferon-alpha as an adjunct therapy in managing viral respiratory infections in infants.